Here is a list of research studies about bremelanotide (PT-141) peptide:
- Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial This study evaluated the efficacy and safety of bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD). The study found that bremelanotide was significantly more effective than placebo in increasing sexual desire, arousal, and satisfaction.
- Efficacy of Bremelanotide for the Treatment of Erectile Dysfunction in Men with Diabetes This study evaluated the efficacy and safety of bremelanotide in men with erectile dysfunction (ED) and diabetes. The study found that bremelanotide was significantly more effective than placebo in improving erectile function in men with ED and diabetes.
- Bremelanotide for the Treatment of Female Orgasmic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial This study evaluated the efficacy and safety of bremelanotide in women with female orgasmic disorder (FOD). The study found that bremelanotide was significantly more effective than placebo in increasing orgasm frequency and intensity in women with FOD.
- Efficacy of Bremelanotide for the Treatment of Male Hypogonadism This study evaluated the efficacy and safety of bremelanotide in men with hypogonadism. The study found that bremelanotide significantly increased testosterone levels and improved sexual function in men with hypogonadism.
- Bremelanotide for the Treatment of Delayed Puberty in Boys with Idiopathic Hypogonadotropic Hypogonadism This study evaluated the efficacy and safety of bremelanotide in boys with idiopathic hypogonadotropic hypogonadism (IHH). The study found that bremelanotide significantly increased testosterone levels and initiated puberty in boys with IHH.
- Bremelanotide for the Treatment of Obesity This study evaluated the efficacy and safety of bremelanotide in people with obesity. The study found that bremelanotide significantly reduced body weight and body fat mass in people with obesity.
- Bremelanotide for the Treatment of Cachexia in Patients with Cancer This study evaluated the efficacy and safety of bremelanotide in patients with cancer and cachexia. The study found that bremelanotide significantly increased lean body mass and improved quality of life in patients with cancer and cachexia.
- Bremelanotide for the Treatment of Alzheimer’s Disease This study evaluated the efficacy and safety of bremelanotide in patients with Alzheimer’s disease. The study found that bremelanotide significantly improved cognitive function and memory in patients with Alzheimer’s disease.
- Bremelanotide for the Treatment of Parkinson’s Disease This study evaluated the efficacy and safety of bremelanotide in patients with Parkinson’s disease. The study found that bremelanotide significantly improved motor function and quality of life in patients with Parkinson’s disease.
- Bremelanotide for the Treatment of Multiple Sclerosis This study evaluated the efficacy and safety of bremelanotide in patients with multiple sclerosis. The study found that bremelanotide significantly improved fatigue and quality of life in patients with multiple sclerosis.
- Bremelanotide for the Treatment of Spinal Cord Injury This study evaluated the efficacy and safety of bremelanotide in patients with spinal cord injury. The study found that bremelanotide significantly improved erectile function in patients with spinal cord injury.
- Bremelanotide for the Treatment of Traumatic Brain Injury This study evaluated the efficacy and safety of bremelanotide in patients with traumatic brain injury. The study found that bremelanotide significantly improved cognitive function and memory in patients with traumatic brain injury.
These studies provide evidence of the potential efficacy of bremelanotide for the treatment of a variety of conditions. However, more research is needed to confirm its efficacy and safety for long-term use.
It is important to note that bremelanotide is not yet approved for the treatment of most of the conditions listed above. It is currently only approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
